Ampio Pharmaceuticals (AMPE) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Ampio Pharmaceuticals, Inc. has engaged in an At The Market Offering Agreement with H. C. Wainwright & Co., LLC, allowing for the periodic sale of its common stock. On January 25, 2024, the company filed a Prospectus Supplement to a previously effective Registration Statement, announcing the potential sale of common stock up to $1,315,900. Sales will be conducted through Wainwright, with the common stock being offered only via the Prospectus, and the sale is subject to legal compliance in applicable jurisdictions. Ballard Spahr LLP has provided a legal opinion on the stock offering, which is included in the company’s recent Form 8-K report.
For further insights into AMPE stock, check out TipRanks’ Stock Analysis page.
